Eledon to present Phase 2 BESTOW kidney transplant trial patient-reported outcomes for tegoprubart at ASN Kidney Week 2026
ELDN•Eledon said it will present patient-reported outcomes from its Phase 2 BESTOW kidney transplant trial of tegoprubart versus tacrolimus on Oct. 23, 2026, at ASN Kidney Week in Denver.
1. Presentation scheduled
Eledon flagged new patient-reported outcomes from the Phase 2 BESTOW trial, which compares tegoprubart with tacrolimus in kidney transplant patients. Results have not yet been presented; an oral presentation is scheduled for Oct. 23, 2026, at ASN Kidney Week in Denver.
